Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Løppenthin, Katrine ; Johansen, Christoffer ; Larsen, Matilde Bille ; Forchhammer, Birgitte Hysse ; Brennum, Jannick ; Piil, Karin ; Aaronson, Neil ; Rasmussen, Birthe Krogh ; Bidstrup, Pernille. / Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group. I: National Comprehensive Cancer Network. Journal. 2020 ; Bind 18, Nr. 9. s. 1222-1229.

Bibtex

@article{ea7e0f090b8b4b5091717539f65fa5b2,
title = "Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group",
abstract = "Background: It is well established that patients with glioma may experience adverse general (eg, headache) or focal symptoms (eg, personality changes) and neurocognitive deficits (eg, planning), but they may also experience severe emotional distress. We investigated the prevalence of depressive symptoms in patientswith newly diagnosed glioma and in matched cancer-free persons. Methods: For this study, we recruited patients with glioma diagnosed within 12 months at all 4 neurosurgical clinics in Denmark. The cancer-free comparison group was identified through the Danish Central Person Register and matched on sex and age. Participants' depressive symptoms were evaluated using the Center for Epidemiologic Studies Depression Scale (CES-D; score range, 0-60), with a cutoff score ≥16 indicating moderate-to-severe depressive symptoms. Results: In this study, 363 of 554 patients with glioma and 481 of 1,304 cancer-free persons participated. Mean age of all patients was 55 years and 60% of the population was male. Mean scores for depressive symptoms were statistically significantly higher among patients with glioma, with a mean CES-D score of 10.9 (95% CI, 10.1-11.8) compared with 5.3 (95% CI, 4.7-5.8) among cancer-free persons (P<.0001). Overall, 92 patients with glioma (25%) and 30 cancer-free persons (6%) had moderate-to-severe depressive symptoms. After adjustment for marital status, education level, and comorbidity, the prevalence of depressive symptoms was 5 times higher among patients with glioma compared with cancer-free persons. Conclusions: A substantially higher prevalence of moderate-tosevere depressive symptoms was identified in patients with glioma compared with cancer-free persons. This indicates the importance of programs to systematically identify and manage depressive symptoms in patients with glioma.",
author = "Katrine L{\o}ppenthin and Christoffer Johansen and Larsen, {Matilde Bille} and Forchhammer, {Birgitte Hysse} and Jannick Brennum and Karin Piil and Neil Aaronson and Rasmussen, {Birthe Krogh} and Pernille Bidstrup",
year = "2020",
month = sep,
doi = "10.6004/jnccn.2020.7570",
language = "English",
volume = "18",
pages = "1222--1229",
journal = "National Comprehensive Cancer Network. Journal",
issn = "1540-1405",
publisher = "Harborside Press",
number = "9",

}

RIS

TY - JOUR

T1 - Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

AU - Løppenthin, Katrine

AU - Johansen, Christoffer

AU - Larsen, Matilde Bille

AU - Forchhammer, Birgitte Hysse

AU - Brennum, Jannick

AU - Piil, Karin

AU - Aaronson, Neil

AU - Rasmussen, Birthe Krogh

AU - Bidstrup, Pernille

PY - 2020/9

Y1 - 2020/9

N2 - Background: It is well established that patients with glioma may experience adverse general (eg, headache) or focal symptoms (eg, personality changes) and neurocognitive deficits (eg, planning), but they may also experience severe emotional distress. We investigated the prevalence of depressive symptoms in patientswith newly diagnosed glioma and in matched cancer-free persons. Methods: For this study, we recruited patients with glioma diagnosed within 12 months at all 4 neurosurgical clinics in Denmark. The cancer-free comparison group was identified through the Danish Central Person Register and matched on sex and age. Participants' depressive symptoms were evaluated using the Center for Epidemiologic Studies Depression Scale (CES-D; score range, 0-60), with a cutoff score ≥16 indicating moderate-to-severe depressive symptoms. Results: In this study, 363 of 554 patients with glioma and 481 of 1,304 cancer-free persons participated. Mean age of all patients was 55 years and 60% of the population was male. Mean scores for depressive symptoms were statistically significantly higher among patients with glioma, with a mean CES-D score of 10.9 (95% CI, 10.1-11.8) compared with 5.3 (95% CI, 4.7-5.8) among cancer-free persons (P<.0001). Overall, 92 patients with glioma (25%) and 30 cancer-free persons (6%) had moderate-to-severe depressive symptoms. After adjustment for marital status, education level, and comorbidity, the prevalence of depressive symptoms was 5 times higher among patients with glioma compared with cancer-free persons. Conclusions: A substantially higher prevalence of moderate-tosevere depressive symptoms was identified in patients with glioma compared with cancer-free persons. This indicates the importance of programs to systematically identify and manage depressive symptoms in patients with glioma.

AB - Background: It is well established that patients with glioma may experience adverse general (eg, headache) or focal symptoms (eg, personality changes) and neurocognitive deficits (eg, planning), but they may also experience severe emotional distress. We investigated the prevalence of depressive symptoms in patientswith newly diagnosed glioma and in matched cancer-free persons. Methods: For this study, we recruited patients with glioma diagnosed within 12 months at all 4 neurosurgical clinics in Denmark. The cancer-free comparison group was identified through the Danish Central Person Register and matched on sex and age. Participants' depressive symptoms were evaluated using the Center for Epidemiologic Studies Depression Scale (CES-D; score range, 0-60), with a cutoff score ≥16 indicating moderate-to-severe depressive symptoms. Results: In this study, 363 of 554 patients with glioma and 481 of 1,304 cancer-free persons participated. Mean age of all patients was 55 years and 60% of the population was male. Mean scores for depressive symptoms were statistically significantly higher among patients with glioma, with a mean CES-D score of 10.9 (95% CI, 10.1-11.8) compared with 5.3 (95% CI, 4.7-5.8) among cancer-free persons (P<.0001). Overall, 92 patients with glioma (25%) and 30 cancer-free persons (6%) had moderate-to-severe depressive symptoms. After adjustment for marital status, education level, and comorbidity, the prevalence of depressive symptoms was 5 times higher among patients with glioma compared with cancer-free persons. Conclusions: A substantially higher prevalence of moderate-tosevere depressive symptoms was identified in patients with glioma compared with cancer-free persons. This indicates the importance of programs to systematically identify and manage depressive symptoms in patients with glioma.

UR - http://www.scopus.com/inward/record.url?scp=85090508092&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.7570

DO - 10.6004/jnccn.2020.7570

M3 - Journal article

C2 - 32886907

VL - 18

SP - 1222

EP - 1229

JO - National Comprehensive Cancer Network. Journal

JF - National Comprehensive Cancer Network. Journal

SN - 1540-1405

IS - 9

ER -

ID: 60936868